Literature DB >> 21503784

[Cutaneous side effects of medical tumor therapy].

A Degen1, M Alter, F Schenck, A Kapp, R Gutzmer.   

Abstract

Agents used in medical tumor therapies can cause peculiar cutaneous side effects. In particular the newly developed targeted therapies are associated with specific cutaneous side effects, such as a papulopustular exanthems associated with EGFR inhibitors and epithelial skin cancers associated with inhibitors of mutated BRAF. In this review the clinical pictures as well as pathogenetic and therapeutic aspects of the hand-foot-syndrome, papulopustular exanthems, epithelial skin cancers, paronychia and changes of hair and nails as side effects of medical tumor therapies are summarized. Knowledge of these side effects is important to avoid interruption or termination of the tumor therapy, in particular since some of the cutaneous reactions have been shown to correlate with the therapeutic benefit of the tumor therapy.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21503784     DOI: 10.1007/s00105-010-2042-4

Source DB:  PubMed          Journal:  Hautarzt        ISSN: 0017-8470            Impact factor:   0.751


  30 in total

Review 1.  Does basal cell carcinoma belong to the spectrum of sorafenib-induced epithelial skin cancers?

Authors:  A Degen; I Satzger; B Voelker; A Kapp; A Hauschild; R Gutzmer
Journal:  Dermatology       Date:  2010       Impact factor: 5.366

2.  Successful treatment with oral isotretinoin of acneiform skin lesions associated with cetuximab therapy.

Authors:  R Gutzmer; T Werfel; R Mao; A Kapp; J Elsner
Journal:  Br J Dermatol       Date:  2005-10       Impact factor: 9.302

3.  [Cutaneous side effects of EGF-receptor inhibition and their management].

Authors:  R Gutzmer; T Werfel; A Kapp; J Elsner
Journal:  Hautarzt       Date:  2006-06       Impact factor: 0.751

4.  Keratoacanthomas and squamous cell carcinomas in patients receiving sorafenib.

Authors:  Jean Philippe Arnault; Janine Wechsler; Bernard Escudier; Alain Spatz; Gorana Tomasic; Vincent Sibaud; Selim Aractingi; Jean-Didier Grange; Vichnou Poirier-Colame; David Malka; Jean-Charles Soria; Christine Mateus; Caroline Robert
Journal:  J Clin Oncol       Date:  2009-07-13       Impact factor: 44.544

Review 5.  The hand-foot-syndrome associated with medical tumor therapy - classification and management.

Authors:  Annette Degen; Mareike Alter; Florian Schenck; Imke Satzger; Bernward Völker; Alexander Kapp; Ralf Gutzmer
Journal:  J Dtsch Dermatol Ges       Date:  2010-05-06       Impact factor: 5.584

Review 6.  Cutaneous side effects of epidermal growth factor receptor inhibitors: clinical presentation, pathogenesis, and management.

Authors:  Jenny C Hu; Parrish Sadeghi; Lauren C Pinter-Brown; Sharona Yashar; Melvin W Chiu
Journal:  J Am Acad Dermatol       Date:  2006-12-01       Impact factor: 11.527

7.  Eruptive keratoacanthoma-type squamous cell carcinomas in patients taking sorafenib for the treatment of solid tumors.

Authors:  Kathleen J Smith; Heather Haley; Sate Hamza; Henry G Skelton
Journal:  Dermatol Surg       Date:  2009-07-29       Impact factor: 3.398

8.  Pooled safety analysis of BAY 43-9006 (sorafenib) monotherapy in patients with advanced solid tumours: Is rash associated with treatment outcome?

Authors:  D Strumberg; A Awada; H Hirte; J W Clark; S Seeber; P Piccart; E Hofstra; D Voliotis; O Christensen; A Brueckner; B Schwartz
Journal:  Eur J Cancer       Date:  2006-01-19       Impact factor: 9.162

9.  Docetaxel (taxotere) induced subacute cutaneous lupus erythematosus: report of 4 cases.

Authors:  Michael Chen; A Neil Crowson; Melinda Woofter; Mary Beth Luca; Cynthia M Magro
Journal:  J Rheumatol       Date:  2004-04       Impact factor: 4.666

10.  Hand foot skin reaction in cancer patients treated with the multikinase inhibitors sorafenib and sunitinib.

Authors:  M E Lacouture; L M Reilly; P Gerami; J Guitart
Journal:  Ann Oncol       Date:  2008-06-10       Impact factor: 32.976

View more
  1 in total

1.  [Cutaneous side effects of anti-tumor therapy with BRAF and MEK inhibitors].

Authors:  R Gutzmer; J C Hassel; K C Kähler; C Loquai; R Mössner; S Ugurel; L Zimmer; Für Komitee Kutane Nebenwirkungen Ado der das Ado
Journal:  Hautarzt       Date:  2014-07       Impact factor: 0.751

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.